

**Food and Drug Administration**  
**Center for Drug Evaluation and Research**  
*Oncologic Drugs Advisory Committee Meeting*  
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center  
(Rm. 1503), Silver Spring, MD  
**March 20, 2012**

---

**DRAFT MEETING ROSTER**

---

**DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Caleb Briggs, Pharm.D.**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs  
Center for Drug Evaluation and Research

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Deborah K. Armstrong, M.D.**

Associate Professor of Oncology  
The Sidney Kimmel Comprehensive Cancer  
Center at Johns Hopkins  
The Johns Hopkins University School of  
Medicine  
Baltimore, Maryland

**Frank Balis, M.D.**

The Louis and Amelia Canuso Family Endowed  
Chair for Clinical Research in Oncology  
The Children's Hospital of Philadelphia  
University of Pennsylvania School of Medicine  
Philadelphia, Pennsylvania

**Ralph Freedman, M.D., Ph.D.**

Clinical Professor  
Department of Gynecologic Oncology  
The University of Texas  
M.D. Anderson Cancer Center  
Houston, Texas

**Wm Kevin Kelly, D.O.**

Professor, Medical Oncology and Urology  
Director, Division of Solid Tumor Oncology  
Associate Director, Translational Research  
Thomas Jefferson University  
Philadelphia, Pennsylvania

**Brent Logan, Ph.D.**

Professor of Biostatistics  
Division of Biostatistics  
Medical College of Wisconsin  
Milwaukee, Wisconsin

**Mikael Sekeres, M.D., M.S.**

Associate Professor of Medicine  
Staff, Cleveland Clinic Taussig Cancer Institute  
Department of Hematologic Oncology and  
Blood Disorders  
Cleveland, Ohio

**Wyndham Wilson, M.D., Ph.D. (Chairperson)**

Chief, Lymphoma Therapeutics Section  
Metabolism Branch  
Center for Cancer Research  
National Cancer Institute (NCI)  
National Institutes of Health (NIH)  
Rockville, Maryland

**Jane Zones, Ph.D. (Consumer Representative)**

Medical Sociologist (retired)  
Breast Cancer Action  
National Women's Health Network  
San Francisco, California

**Food and Drug Administration**  
**Center for Drug Evaluation and Research**  
*Oncologic Drugs Advisory Committee Meeting*  
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center  
(Rm. 1503), Silver Spring, MD  
**March 20, 2012**

**DRAFT MEETING ROSTER (cont.)**

---

**ACTING INDUSTRY REPRESENTATIVE TO THE ONCOLOGIC DRUGS ADVISORY COMMITTEE**  
**(Non-Voting)**

**Howard Fingert, M.D., F.A.C.P.**

*(Acting Industry Representative)*

Senior Medical Director, Clinical Intelligence  
Millennium, the Takeda Oncology Company  
Cambridge, Massachusetts

**TEMPORARY MEMBERS (Voting)**

**Aman U. Buzdar, M.D. (Afternoon Session Only)**

Vice President Clinical Research and Interim  
Professor of Medicine  
M.D. Anderson Cancer Center  
Dept. of Breast Medical Oncology  
Houston, Texas

**Ephraim Casper, M.D.**

Head, Division of Network Medicine Services  
Department of Medicine  
Memorial Hospital  
Memorial Sloan-Kettering Cancer Center  
New York, New York

**Lee J. Helman, M.D.**

Scientific Director for Clinical Research  
Center for Cancer Research  
National Cancer Institute (NCI)  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Leo Mascarenhas, M.D., M.S.**

Associate Professor of Pediatrics  
Keck School of Medicine/University of  
Southern California  
Director -Clinical Trials Office  
Children's Center for Cancer and Blood Diseases  
Childrens Hospital Los Angeles  
Los Angeles, California

**Angela Myers, M.D., M.P.H. (Morning Session Only)**

*(Patient Representative)*  
Lenexa, Kansas

**Kareem Shaya (Afternoon Session Only)**

*(Patient Representative)*  
Lutherville, Maryland

**Food and Drug Administration**  
**Center for Drug Evaluation and Research**  
*Oncologic Drugs Advisory Committee Meeting*  
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center  
(Rm. 1503), Silver Spring, MD  
**March 20, 2012**

**DRAFT MEETING ROSTER (cont.)**

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, M.D.**

Director, Office of Hematology and Oncology  
Products (OHOP),  
Office of New Drugs (OND), CDER, FDA

**Robert Justice, M.D.**

Director  
Division of Oncology Products 1 (DOP1),  
OHOP, OND, CDER, FDA

**V. Ellen Maher, M.D. (Afternoon Session Only)**

Medical Team Leader  
DOP1, OHOP, OND, CDER, FDA

**Gwynn Ison, M.D. (Afternoon Session Only)**

Medical Officer  
DOP1, OHOP, OND, CDER, FDA

**Amir Shahlaee, M.D. (Morning Session Only)**

Medical Officer  
DOP1, OHOP, OND, CDER, FDA

**Lijun Zhang, Ph.D. (Morning Session Only)**

Statistical Reviewer  
Division of Biostatistics V (DBV),  
Office of Biostatistics (OB),  
Office of Translational Science (OTS),  
CDER, FDA

**Huanyu (Jade) Chen, Ph.D. (Afternoon Session Only)**

Statistical Reviewer  
DBV, OB, OTS, CDER, FDA